Neurodegenerative disease companies develop therapeutics, diagnostics and research technologies for conditions involving the progressive loss of neurons and nervous system function. Their work aims to improve disease detection, slow progression and address the underlying biology of neurodegeneration.
This category includes companies working on:
Browse 109 UK neurodegenerative disease companies below.
AI and photonics platform for personalised drug development
iLoF is a digital health company developing an AI-powered platform that uses proprietary photonics technology to generate optical fingerprints from blood samples, building a cloud-based library of biological profiles and biomarkers. The platform enables non-invasive patient stratification and personalised drug…
Exosome-delivered gene editing therapies for neurodegenerative diseases
Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies for rare, genetically driven neurodegenerative diseases. Its proprietary platform uses engineered exosomes to deliver CRISPR-based gene editors across the blood-brain barrier, enabling targeted genetic intervention in the…
AI genomics for drug target discovery
OutSee is a genomics and drug discovery company using proprietary AI technology to identify and validate novel therapeutic targets. Its core platform applies predictive algorithms to large-scale genomic datasets to uncover disease-modulating biological mechanisms, complementing traditional analysis methods. OutSee…
High-throughput iPSC reprogramming and stem cell drug discovery services
Oxford StemTech is a contract research company providing induced pluripotent stem cell (iPSC) reprogramming and drug discovery services using its proprietary platform. The technology enables large-scale, cost-effective generation of patient-derived iPSC lines from blood or skin samples, supporting disease modelling,…
Europe's largest biomedical discovery institute researching the biology of disease
The Francis Crick Institute is a biomedical discovery institute researching the biology underlying human health and disease. The Institute studies biology from molecules to entire organisms, translating discoveries into new ways to treat illnesses including cancer, heart disease and neurodegenerative conditions.…
Therapeutics targeting lysosomal dysfunction in neurodegeneration
Endlyz Therapeutics is a preclinical-stage biotechnology company developing small molecule modulators to restore endo-lysosomal function in Parkinson's disease and related neurodegenerative conditions. Its lead programmes target ATP13A2 and ATP10B, lysosomal transporter enzymes linked to neuronal health and…
AAV gene therapies for rare neurological diseases of childhood
BlackfinBio is a biotechnology company developing AAV-based gene therapies for rare neurodegenerative diseases of the central nervous system, with an initial focus on children. Its lead programme is a one-time gene therapy administered directly to the brain, designed to treat a group of ultra-rare dopamine deficiency…
Novel peptide-based therapeutics and biomarkers for neurodegeneration
Neuro-Bio is a preclinical-stage biotechnology company developing a first-in-class therapeutic approach to Alzheimer's disease and related neurodegenerative disorders. Its research centres on T14, a 14 amino acid bioactive peptide derived from acetylcholinesterase, which the company has identified as a potential…
Rare and serious disease therapeutics with Cambridge R&D hub
Insmed is a US biopharmaceutical company with commercial-stage and late-pipeline products spanning respiratory, inflammatory and rare neurological diseases. Its Cambridge facility at Babraham Research Campus, established through the 2023 acquisition of Adrestia, leads drug discovery using the company's synthetic…
Multiplexed LC-MS proteomics for biomarker development and clinical trials
Inoviv is a bioanalytical contract research company providing multiplexed, quantitative LC-MS targeted proteomics services to pharmaceutical and biotech clients. Its platform supports biomarker discovery, patient stratification, companion diagnostic development, and treatment efficacy monitoring across clinical and…
Human iPSC-derived disease models and drug discovery services
Axol Bioscience is a biotechnology company supplying human induced pluripotent stem cell-derived cells and research services for disease modelling and drug discovery. Its portfolio includes neurons, cardiomyocytes, retinal organoids, retinal pigment epithelium and skin cell models, alongside culture media and custom…
Global biopharma with UK R&D hub in Hertfordshire
Roche Products is the UK pharmaceutical arm of F. Hoffmann-La Roche, headquartered at Welwyn Garden City in Hertfordshire. The site employs over 1,900 people and serves as a primary hub for early-stage drug discovery, clinical development, computational sciences, and commercial operations. The UK operation contributes…
AAV gene therapies for rare and neurological diseases
Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus-based gene therapies for serious chronic diseases. Its lead programme is a Phase I/II gene therapy for Gaucher disease type 1, a rare lysosomal storage disorder. Further pipeline candidates target GBA1 Parkinson's disease and…
Systems biology platform for brain disease drug discovery and repurposing
BRAINCURES is a computational biotechnology company applying a systems biology approach to drug discovery for brain diseases, including Alzheimer's disease, depression, epilepsy, pain and schizophrenia. Its platform maps molecular relationships between compounds, genes and diseases, drawing on its own model of the…
Single-cell omics analysis platform for precision neuroscience research
CellClar is a UK-based Community Interest Company developing an AI-assisted software platform for single-cell omics data analysis in precision medicine. Its flagship product is designed to transform complex single-cell sequencing datasets into actionable insights for researchers working on neurodegenerative diseases,…
AI drug discovery platform targeting neurological diseases
CoSyne Therapeutics is a drug discovery company applying AI and computational methods to identify and develop therapeutics for neurological diseases. The company describes its approach as polymathic AI, integrating models across biology, chemistry, and genomics to generate and prioritise drug targets. CoSyne operates…
Ex vivo haematopoietic stem cell gene therapies for rare genetic diseases
Orchard Therapeutics is a gene therapy company developing ex vivo haematopoietic stem cell therapies for rare genetic diseases, primarily severe neurometabolic and immunological disorders in children. Its platform modifies a patient's own stem cells with a functional copy of the defective gene before reinfusion. Lead…
AAV gene therapies for neurodegenerative diseases including FTD and ALS
AviadoBio is a clinical-stage gene therapy company developing AAV-based treatments for neurodegenerative diseases. Its lead programme, AVB-101, is in a Phase 1/2 trial for frontotemporal dementia caused by GRN gene mutations, delivering a functional copy of the GRN gene via intrathalamic infusion to restore…
Integrated academic drug discovery facility for anti-infectives and innovative targets
The Drug Discovery Unit is an academic drug discovery facility at the University of Dundee, integrating medicinal chemistry, high-throughput screening, structural biology, cell biology, and DMPK in a single purpose-built facility. The DDU conducts small molecule drug discovery programmes across two areas:…
AI-driven neuroimaging analytics for clinical trials
Queen Square Analytics is a UCL spin-out providing advanced neuroimaging data analytics for neurological clinical trials. The company applies machine learning to MRI data for patient stratification, treatment response prediction, and imaging protocol design, with a primary focus on multiple sclerosis and…